Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

4 de janeiro de 2022 atualizado por: SCRI Development Innovations, LLC

Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/refractory Multiple Myeloma (MM) is an incurable disorder with a poor prognosis. Carfilzomib is a novel proteasome inhibitor with activity in this setting. Panobinostat is a pan-deacetylase inhibitor which has shown synergistic cytotoxicity in vitro and in vivo with proteasome inhibitors. The combination should enhance the activity of both agents against myeloma cells. In Phase I, the optimal doses of the combination of carfilzomib and panobinostat will be determined. Assuming this combination is feasible, the Phase II portion will proceed using the doses determined in Phase I.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

In this open-label, non-randomized Phase I/II study, a maximum of 4 planned dose levels of carfilzomib and panobinostat were evaluated to determine the maximum tolerated dose (MTD) to administer. The MTD was not reached so patients in Phase II received treatment at dose level 4 to further assess efficacy. Response to treatment was evaluated after each 4-week cycle. Those having an objective response or stable disease are continuing treatment until disease progression or unacceptable toxicity occurs.

As the MTD in the 4 planned dose levels were not reached, a parallel Phase I study was initiated to examine additional dose levels using a traditional 3+3 design. If these dose levels are tolerable, then more patients will be recruited into an expansion cohort to assess efficacy at the new dose level(s).

Tipo de estudo

Intervencional

Inscrição (Real)

80

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Estados Unidos
    • Colorado
      • Denver, Colorado, Estados Unidos, 80218
        • Colorado Blood Cancer Institute
    • Florida
      • Fort Myers, Florida, Estados Unidos, 33916
        • Florida Cancer Specialists South
      • Pensacola, Florida, Estados Unidos, 32503
        • Woodlands Medical Specialists
      • Saint Petersburg, Florida, Estados Unidos, 33705
        • Florida Cancer Specialists North
    • Indiana
      • Terre Haute, Indiana, Estados Unidos, 47802
        • Providence Medical Group
      • Terre Haute, Indiana, Estados Unidos, 47802
        • RHHP/Hope Cancer Center
    • Missouri
      • Kansas City, Missouri, Estados Unidos, 64132
        • Research Medical Center
    • New Jersey
      • Morristown, New Jersey, Estados Unidos, 07962
        • Hematology-Oncology Associates - Northern NJ
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45242
        • Oncology Hematology Care, Inc.
    • Oklahoma
      • Lawton, Oklahoma, Estados Unidos, 73505
        • Cancer Centers of Southwest Oklahoma
    • Tennessee
      • Chattanooga, Tennessee, Estados Unidos, 37404
        • Tennessee Oncology-Chattanooga
      • Nashville, Tennessee, Estados Unidos, 37205
        • Tennessee Oncology
    • Texas
      • Fort Worth, Texas, Estados Unidos, 76104
        • The Center for Cancer and Blood Disorders

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Eligible participants must have multiple myeloma using standard criteria.

  2. Patients must have measurable disease requiring systemic therapy defined as at least one of the following:

    • Serum M-protein ≥1 g/dl (≥10 g/l)
    • Urine M-protein ≥200 mg/24 hrs
    • Serum free light chain assay: involved free light chain level ≥10 mg/dl (≥100 mg/l) provided the serum free light chain ratio is abnormal
  3. Must have progressed during or after at least one previous bortezomib-containing treatment regimen. Patients who have received previous high-dose therapy/autologous stem cell transplantation are eligible.
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

  5. Must meet the following laboratory criteria:

    • Absolute neutrophil count (ANC) ≥1000/μL;
    • Platelets ≥70,000/microL;
    • AST or ALT and alkaline phosphatase (ALP) must be ≤ 2.5 x ULN, or ≤ 5 x ULN in patients with plasmacytomas of the liver;
    • Total bilirubin ≤ 1.5 x the institutional ULN;
    • Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 50 ml/min;
    • Serum potassium, calcium, magnesium WNL (These may be corrected prior to starting therapy, to make the patient eligible.)
  6. Ability to swallow oral medications.
  7. Baseline MUGA or ECHO must demonstrate left ventricular ejection fraction (LVEF) ≥ the lower limit of the institutional limits of normal.
  8. Male or females ≥ 18 years of age.
  9. Female patients must not be of child-bearing potential or must agree to use adequate contraceptive measures.
  10. Male patients willing to use adequate contraceptive measures.
  11. Willingness and ability to comply with the trial and follow-up procedures.
  12. Ability to understand the nature of this trial and give written informed consent.

Exclusion Criteria:

  1. Currently receiving or have received systemic cancer therapy (chemotherapy, biologic therapy) ≤ 21 days of initiating study therapy. For patients receiving small molecule targeted therapy, study treatment may begin >21 days after last dose or >5 half lives of previous treatment, whichever is shorter. Patients must have completed radiation therapy ≥7 days prior to starting study treatment. Patients must have recovered from or come to a new chronic stable baseline from all treatment-related toxicities. Dexamethasone or other high-dose steroid therapy must be stopped ≥ days prior to starting study treatment.
  2. Previous treatment with HDAC, DAC, HSP90 or valproic acid for treatment of cancer.
  3. Requires valproic acid for any medical condition during the study ≤5 days prior to first panobinostat treatment.
  4. Patient has not recovered from all therapy-related toxicities associated with prior treatments to < Grade 2 CTCAE.
  5. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).
  6. Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis ≤14 days prior to study entry.
  7. Patients using medications that have a risk of prolonging the QT interval or inducing Torsade de Pointes if treatment cannot be discontinued or switched to a different medication prior to receiving study drug.
  8. Patients with > grade 2 diarrhea.
  9. Patients with impaired cardiac function.
  10. Infection requiring IV antibiotics.
  11. Patients with > grade 2 peripheral neuropathy or with uncontrolled pain.
  12. Women who are pregnant or lactating.
  13. Any concurrent medical illness that may impair the ability of the patient to tolerate study treatment and comply with the requirements of the study.
  14. Mental condition that would prevent patient comprehension of the nature of, and risk associated with, the study.
  15. Use of any non-approved or investigational agent ≤30 days prior to administration of the first dose of study drug. Patients may not receive any other investigational or anti-cancer treatments while participating in this study.
  16. Presence of other active cancers, or history of treatment for invasive cancer ≤ 5 years. Patients with stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e. non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Carfilzomib and Panobinostat

Phase I:

Carfilzomib: cycle 1 - Dose is 20 mg/m^2 IV on day 1; 27 or 36 or 45 or 56 mg/m^2 IV on Days 8, 9, 15, 16 cycle 2 to progression - 27 or 36 or 45 or 56 mg/m^2 IV on days 1, 2, 8, 9, 15, 16

Panobinostat: cycle 1 and cycle 2 to progression - 20 mg or 30 mg on days 1, 3, 5, 15, 17, 19

Phase II:

Carfilzomib and Panobinostat: Dose is optimal dose determined in Phase I
Medicamento: panobinostat
Specified dose on specified days
Outros nomes:
  • LBH589 (Panobinostat)
Medicamento: carfilzomib
Specified dose on specified days
Outros nomes:
  • PX-171-007

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage
Prazo: 28 days from the start of study treatment

Using a traditional 3+3 dose escalation design, successive cohorts of subjects will receive a fixed dose level of the drug combination. The MTD is defined as the highest dose level at which ≤1 of 6 subjects experiences a dose-limiting toxicity (DLT) assessed by NCI CTCAE v4.0. DLT is defined as any of the following that are determined to be related to study treatment during Cycle 1:

Grade 4 neutropenia for >7 days, Febrile neutropenia, Grade 3 thrombocytopenia with ≥ Grade 2 bleeding, Grade 4 thrombocytopenia > 7 days, ≥ Grade 2 neuropathy with uncontrolled pain, ≥ Grade 3 non-hematologic drug-related toxicity (excluding alopecia), despite optimal supportive care lasting >72 hours or requiring a dose reduction in the first cycle and Patients who are unable to receive 75% of the required doses of both agents secondary to toxicity. Number of Participants With such Dose Limiting Toxicities (DLT) at each level are reported here.
28 days from the start of study treatment
Phase II: Overall Response Rate
Prazo: up to 6 years
Defined as the percentage of patients with confirmed complete response, very good partial response, or partial response (CR, VGPR, or PR) according to International Myeloma Working Group Uniform Response Criteria. CR=bone marrow contains ≤5% plasma cells; negative fixation on serum and urine; disappearance of soft tissue plasmacytomas. VGPR=≥90% reduction from baseline serum; urine M-protein level 100mg for 24h. PR=≥50% reduction from baseline in serum M-protein; disappearance of any soft tissue plasmacytomas.
up to 6 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Time-to-progression (TTP)
Prazo: up to 6 years
Measured from date of first treatment until date of first documented progression as per International Myeloma Working Group Uniform Response Criteria. Progressive disease id defined as an increase of ≥ 25% from the nadir in at least one of the following criteria: serum M-protein (absolute increase must be ≥0.5 g/dL); urine M-protein (absolute increase must be ≥200 mg/24h) ; only in patients with non-measurable serum and urine M-protein levels: difference in involved and uninvolved FLC levels (absolute increase must be >10 mg/dL); only in patients with non-measurable serum and urine M-protein levels and non-measurable disease by FLC levels, bone marrow plasma cell percentage (absolute % must be ≥10%) OR Definite development of new bone lesions or soft tissue plasmacytomas OR definite increase in the size of existing bone lesions or soft tissue plasmacytomas OR Development of hypercalcemia (corrected serum Ca >11.5mg/dL) for patients without hypercalcemia at baseline
up to 6 years
Progression-free-survival (PFS)
Prazo: up to 6 years
Measured from date of first protocol treatment until date of tumor progression or death as per International Myeloma Working Group Uniform Response Criteria. Progressive disease id defined as an increase of ≥ 25% from the nadir in at least one of the following criteria: serum M-protein (absolute increase must be ≥0.5 g/dL); urine M-protein (absolute increase must be ≥200 mg/24h) ; only in patients with non-measurable serum and urine M-protein levels: difference in involved and uninvolved FLC levels (absolute increase must be >10 mg/dL); only in patients with non-measurable serum and urine M-protein levels and non-measurable disease by FLC levels, bone marrow plasma cell percentage (absolute % must be ≥10%) OR Definite development of new bone lesions or soft tissue plasmacytomas OR definite increase in the size of existing bone lesions or soft tissue plasmacytomas OR Development of hypercalcemia (corrected serum Ca >11.5mg/dL) for patients without hypercalcemia at baseline
up to 6 years
Overall-survival (OS)
Prazo: up to 6 years
Measured from time of first study treatment until date of death or date last known alive.
up to 6 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

SCRI Development Innovations, LLC

Colaboradores

Novartis
Onyx Therapeutics, Inc.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de dezembro de 2011

Conclusão Primária (Real)

1 de dezembro de 2020

Conclusão do estudo (Real)

1 de dezembro de 2020

Datas de inscrição no estudo

Enviado pela primeira vez

15 de dezembro de 2011

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de dezembro de 2011

Primeira postagem (Estimativa)

21 de dezembro de 2011

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de fevereiro de 2022

Última atualização enviada que atendeu aos critérios de controle de qualidade

4 de janeiro de 2022

Última verificação

1 de janeiro de 2022

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • SCRI MM 27

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever